絞り込み

17791

広告

「"Fahrleitner-Pammer A "[Author]」の検索結果

119件中 1件~20件表示    検索結果をPubMedで見る PubMedで見る

Efficacy of teriparatide compared with risedronate on FRAX-defined major osteoporotic fractures: results of the VERO clinical trial.

Distribution of Prevalent and Incident Vertebral Fractures and Their Association with Bone Mineral Density in Postmenopausal Women in the Teriparatide Versus Risedronate VERO Clinical Trial.

Mind the gap: Incidence of osteoporosis treatment after an osteoporotic fracture - Results of the Austrian branch of the International Costs and Utilities Related to Osteoporotic Fractures Study (ICUROS).

Long-term denosumab treatment restores cortical bone loss and reduces fracture risk at the forearm and humerus: analyses from the FREEDOM Extension cross-over group.

Serum 25-hydroxy-vitamin D and the risk of fractures in the teriparatide versus risedronate VERO clinical trial.

Assessing the effects of long-term osteoporosis treatment by using conventional spine radiographs: results from a pilot study in a sub-cohort of a large randomized controlled trial.

Prescreening for Osteoporosis With Quantitative Ultrasound in Postmenopausal White Women.

Bone matrix hypermineralization associated with low bone turnover in a case of Nasu-Hakola disease.

Teriparatide treatment increases mineral content and volume in cortical and trabecular bone of iliac crest: a comparison of infrared imaging with X-ray-based bone assessment techniques.

The Bone-Cardiovascular Axis: Mechanisms and Clinical Relevance.

Effects of Long-term Denosumab on Bone Histomorphometry and Mineralization in Women With Postmenopausal Osteoporosis.

Bone-related Circulating MicroRNAs miR-29b-3p, miR-550a-3p, and miR-324-3p and their Association to Bone Microstructure and Histomorphometry.

A New Murine Model of Chronic Kidney Disease-Mineral and Bone Disorder.

Effects of Teriparatide Compared with Risedronate on the Risk of Fractures in Subgroups of Postmenopausal Women with Severe Osteoporosis: The VERO Trial.

Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial.

Effect of eplerenone on markers of bone turnover in patients with primary hyperparathyroidism - The randomized, placebo-controlled EPATH trial.

Effect of vitamin D3 on bone turnover markers in critical illness: post hoc analysis from the VITdAL-ICU study.

Plasma parathyroid hormone and cardiovascular disease in treatment-naive patients with primary hyperparathyroidism: The EPATH trial.

Factors associated with high 24-month persistence with denosumab: results of a real-world, non-interventional study of women with postmenopausal osteoporosis in Germany, Austria, Greece, and Belgium.

10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
Sort by
※並べ替えは表示に時間がかかります